key: cord-0933145-rynji67f
authors: Beck, Kristen L.; Seabolt, Ed; Agarwal, Akshay; Nayar, Gowri; Bianco, Simone; Krishnareddy, Harsha; Mukherjee, Vandana; Kaufman, James H.
title: Semi-supervised identification of SARS-CoV-2 molecular targets
date: 2021-05-04
journal: bioRxiv
DOI: 10.1101/2021.05.03.440524
sha: aae779560a6044f0c9e64434d98aeb3ed86de199
doc_id: 933145
cord_uid: rynji67f

SARS-CoV-2 genomic sequencing efforts have scaled dramatically to address the current global pandemic and aid public health. In this work, we analyzed a corpus of 66,000 SARS-CoV-2 genome sequences. We developed a novel semi-supervised pipeline for automated gene, protein, and functional domain annotation of SARS-CoV-2 genomes that differentiates itself by not relying on use of a single reference genome and by overcoming atypical genome traits. Using this method, we identified the comprehensive set of known proteins with 98.5% set membership accuracy and 99.1% accuracy in length prediction compared to proteome references including Replicase polyprotein 1ab (with its transcriptional slippage site). Compared to other published tools such as Prokka (base) and VAPiD, we yielded an 6.4- and 1.8-fold increase in protein annotations. Our method generated 13,000,000 molecular target sequences— some conserved across time and geography while others represent emerging variants. We observed 3,362 non-redundant sequences per protein on average within this corpus and describe key D614G and N501Y variants spatiotemporally. For spike glycoprotein domains, we achieved greater than 97.9% sequence identity to references and characterized Receptor Binding Domain variants. Here, we comprehensively present the molecular targets to refine biomedical interventions for SARS-CoV-2 with a scalable high-accuracy method to analyze newly sequenced infections.

Here, we present a novel semi-supervised pipeline to annotate gene, protein, and functional 89 domain molecular targets from SARS-CoV-2 genomes and demonstrate the resulting accuracy 90 against known reference data and other bioinformatic tools (see Methods). This pipeline pro-91 vides improvements over base Prokka and InterProScan by adding a novel capability that more 92 accurately processes sequences the slippery site junction in Replicase polyprotein 1ab to iden-93 tify the correct sequence which is absent or artificially truncated in other methods. Additionally, 94 we incorporated a targeted search for three key proteins: ORF9b, ORF10, and Envelope small 95 membrane protein which would otherwise be missing in the protein annotation set. We show 96 that our pipeline has an improvement on annotation accuracy by 1.8-and 6.4-fold compared to 97 VAPiD and base Prokka. We also evaluated genome quality from data in public repositories 98 and quantitatively evaluated commonly used quality criteria for their effects on the resulting 99 annotations. For effective genome annotation, an important first step is to assess the quality of the input 102 genomes. In this study, we analyzed a corpus of 66,905 SARS-CoV-2 genomes (Supplemen-103 tary File 1) deposited over the span of eight months from 108 countries into two key aggregate 104 data sources: GISAID (19) and NCBI GenBank (18) . We observed an average of 0.0067% 105 unknown bases (denoted as N per IUPAC definitions) per genome (range 0-46.76%), and all 106 genomes were observed to have less than 1% degenerate bases (Figure 1a) . The presence of 107 unknown bases can indicate insufficient genome coverage or other issues from genome assem-108 bly. Next, we aimed to identify criteria for inclusion of a SARS-CoV-2 genome assembly into 109 our platform to ensure that input data for molecular target identification is of the highest quality. 110 Therefore, we evaluated two commonly used criteria for their effects on prediction of full length 111 protein sequences. Briefly, Criteria A is more permissive and prioritizes the ratio of length vs. 112 coverage whereas Criteria B is more stringent and applies a higher penalty to the number of gaps 113 (detailed definitions in Section 4.1). Here, "full length" is defined as a protein sequence length 114 within 10% of the known UniProt protein reference sequence indicated in the SARS-CoV-2 115 proteome as defined in ViralZone (21, 22) . Figure 1b demonstrates that Criteria A yielded the 116 highest count of full length protein products (35,099 non-redundant protein sequences) while 117 also effectively reducing the majority of truncated products (2,197 non-redundant protein se-118 quences). If applying the more stringent Criteria B, over 14,000 high quality protein products 119 would be inadvertently removed. Based on this, we proceeded with applying the thresholds 120 defined by Criteria A to the corpus of genomes analyzed in this work. From GISAID and 121 GenBank genomes, 9.9% (out of 55,708) and 3.1% (out of 11,197) of genomes fell below this 122 criteria ( Figure 1a ) and are removed from subsequent analysis and marked as inactive unless 123 otherwise mentioned.

As part of our other pre-processing steps for genomic data (20), we computed md5 hashes 125 of all genome sequences to track duplicates. The rate of 'duplicated' SARS-CoV-2 genome 126 sequences within a single data source or between data sources is indicated in Table 1 . From 127 the data at hand, it is unclear whether these duplicated genome sequences as others have ob-128 served (23) (24) (25) are artefacts of data processing e.g. due to alignments to a single reference 129 genome or are a result of sampling multiple patient infections within the same lineage. Of the 130 10,528 genomes that are duplicated within GISAID, we compared the metadata for each entry: Furthermore, not only must the complete set of named genes and proteins be identified for 147 accurate genome annotation, but the generated sequences must also be grounded in biological 148 reality. Specifically, in silico predicted sequences should not be truncated with respect to the length of known references, and the mutational density must be low considering the temporally 150 recent emergence of SARS-CoV-2 and observed lower mutation rate compared to other RNA 151 viruses (16) . Using our semi-supervised gene and protein annotation method (Section 4.2), we 152 were able to identify full length protein products that on a per protein basis match expected Ultimately from this genome corpus, we were able to identify over 13M gene, protein, 171 and functional domain sequences in total ( 

With regard to pipeline accuracy, we benchmarked our pipeline against VAPiD (7), which has 177 created a special release for annotating SARS-CoV-2 genomic data, and Prokka (8), a prokary- was able to identify 6.4-fold more protein products compared to base Prokka and was able to 186 generate full-length pp1ab products with high sequence identity to known UniProt references. We identified the exhaustive set of genes, proteins, and functional domains (Table 2) Figure 1 : SARS-CoV-2 genome quality observations and their effect on annotation results. The percent of unknown (N) and degenerate bases (as defined by IUPAC) are calculated as a function of total genome size for SARS-COV-2 genomes from two sources: NCBI GenBank and GISAID (1a). The quality threshold of unknown bases is indicated with a dashed line. Also, full length (red) or truncated (blue) protein products are indicated for genomes by quality criteria status: our selected criteria (Criteria A), a more stringent criteria (Criteria B), or below quality thresholds (1b). For criteria definitions, see Section 4.1. Count indicates the number of times a given protein was observed in the entire active genome corpus (dashed line). (2b) Protein size distribution of known protein references (expected, green) more closely matches our in silico predicted protein sequences from genomes above quality thresholds (active genomes, red) compared to products predicted from genomes below quality thresholds (inactive genomes, blue). Figure 6 : Spike glycoprotein variants observed in SARS-CoV-2 genomes over time and geography. Each line represents the cumulative frequency per variant (orange: D614G, green: UniProt ID P0DTC2, olive: P1140X, pink: S2 cleavage product) in 6a. Low frequency S protein sequences (<5 observations) are removed from plotting for simplicity. In 6b, the proportion of spike glycoprotein variants differ by exposure region. Proportion is calculated per variant to allow inter-region comparisons.

A new coronavirus associated with human respiratory disease in China

The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 438 (SARS CoV-2 or n-COV19), the Cause of COVID-19

The UCSC SARS-CoV-2 Genome Browser

Genomic determinants of pathogenicity in SARS-CoV-2 and other hu-443 man coronaviruses

A Genomic Perspective on the Origin and Emer-446 gence of SARS-CoV-2

URL /pmc/articles

Structural and functional conservation of the programmed 1 ribosomal 13. US COVID-19 Cases Caused by Variants -CDC

Nextstrain: real-time tracking of pathogen evolution

Fast gapped-read alignment with Bowtie 2

The coronavirus is mutating -does it matter?

Recombination should not be an af-489 terthought

Data, disease and diplomacy: GISAID's innova-495 tive contribution to global health

IBM Functional Genomics Platform, A Cloud-Based Platform for Study-498

UniProt: the universal protein knowledgebase

ViralZone: A knowledge resource to understand virus diversity

Supporting pandemic response using genomics and bioinformatics: A 506 case study on the emergent SARS-CoV-2 outbreak. Transboundary and Emerging Dis-507 eases 67

Accurate online 510 alignment of hCoV-19 genomes using a profile HMM

CoV-Seq, a new tool for SARS-CoV-2 genome analysis and visualization